



A Prospective Study to Evaluate the Efficacy of the Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Chemotherapy Regimen in Patients with Locally Advanced and Metastatic Adenocarcinoma of Stomach

Vijay Kumar Srinivasalu¹ Arun Philip² Ranjini Pillai² Wesley M. Jose² Pavithran Keechilat²

¹Department of Medical Oncology, Mazumdar Shaw Medical Center, Bangalore, Karnataka, India

²Department of Medical Oncology, Amrita Institute of Medical Sciences, Kochi, Kerala, India

Address for correspondence Vijay Kumar Srinivasalu, MD, DM, Department of Medical Oncology, Mazumdar Shaw Medical Center, NH Health City Campus, Bommasandra, Bangalore, Karnataka, 560099, India (e-mail: vjy.doc@gmail.com).

Ind J Med Paediatr Oncol

Abstract

Introduction In India, patients with gastric cancer present at an advanced stage, and there is no standard chemotherapy regimen. Al-Batran's fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy gave us a glimmer of hope.

Objectives Hence, we intended to evaluate the efficacy of FLOT chemotherapy in locally advanced and metastatic adenocarcinoma of stomach.

Materials and Methods In this single-center, prospective cohort, patients with locally advanced and metastatic gastric adenocarcinoma who required chemotherapy between March 2016 and November 2017 were included in the study. All patients received standard FLOT chemotherapy. The primary objective was to evaluate the safety and efficacy of FLOT chemotherapy in the Indian population. Overall survival (OS) and progression-free survival (PFS) were calculated through the plotted Kaplan–Meier curves.

Results In our study, 28 patients received FLOT chemotherapy. Their mean age was 55 years (range, 28–70 years) with a male preponderance (89.3%). Twenty-five patients had metastatic disease (89.3%), and three had locally advanced disease (10.7%). The median number of cycles was 4.5 (range, 1–8), and 75% received at least four cycles ($n = 21$). The hematological toxicities exhibited were neutropenia (50%) and febrile neutropenia (35.7%). Sixteen (57.1%) patients needed dose modifications due to treatment-related adverse effects (AEs). AEs led to treatment discontinuation in seven (25%) patients after the first cycle. The overall response rate in the intent-to-treat population was 52.7%, with the best-obtained response being a partial response, median PFS of 5 months, and median OS of 13 months.

Conclusion FLOT chemotherapy regimens induced excellent responses but with significantly increased toxicity, needing dose modifications, and hence, should be considered only in a young and fit patient.

Keywords

- ▶ adenocarcinoma of the stomach
- ▶ fluorouracil
- ▶ leucovorin
- ▶ oxaliplatin
- ▶ docetaxel chemotherapy
- ▶ locally advanced
- ▶ metastatic

DOI <https://doi.org/10.1055/s-0042-1742445>.
ISSN 0971-5851.

© 2022. Indian Society of Medical and Paediatric Oncology. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Introduction

Gastric cancer is the fifth most common cancer among males and the seventh among females in India. It is also the second most common cause of death globally.^{1,2}

In India, the age-adjusted rate (AAR) of gastric cancer is 3.0 to 13.2, whereas the global AAR for gastric cancer ranges between 4.1 and 95.5.³⁻⁶

Indian patients are usually locally advanced or metastatic at presentation. As weight loss and loss of appetite are a significant concern, treatment with aggressive regimens at full dose to extract maximum benefit from chemotherapy becomes an uphill task. Optimization of a standard regimen to improve survival with minimal toxicities is the need of the hour in gastric cancers.

There is no universal standard chemotherapy regimen in first-line treatment for locally advanced or metastatic adenocarcinoma, and the prognosis is still abysmal with a median survival of 6 to 10 months despite treatment with combination chemotherapy, but for modified docetaxel, cisplatin, and fluorouracil (DCF) regimen by Manish Shah et al documented a median progression-free survival (PFS) and overall survival (OS) of 9.7 and 18.8 months, respectively, in a randomized Phase II study with lesser toxicities in comparison with the standard DCF regimen; however, randomized Phase III trials have shown that combination chemotherapy improved survival and quality of life compared with best supportive care.⁷

In the early days, two-drug combination of fluorouracil (FU) and cisplatin-containing combinations was considered standard therapy for patients with advanced gastric cancer in terms of response rate with no survival benefit.⁸ Later, there was evidence that showed that the addition of DCF was superior to cisplatin and FU alone (CF) in terms of quality of life, response rate, time to progression, and OS.⁹⁻¹¹ Despite these benefits, standard DCF is criticized and not preferred due to its toxicity profile but a modified DCF triplet regimen was considered the standard of care in the first-line treatment of locally advanced and metastatic adenocarcinoma of the stomach.¹²

Several oxaliplatin-based regimens have been evaluated for gastric cancer,¹³⁻¹⁶ with the most intensively investigated regimen being a biweekly (once every 2 weeks) combination of infusional 5-FU (24 hour), leucovorin, and oxaliplatin (FLO).¹⁷⁻¹⁹ This regimen (FLO) has fewer toxicities and thromboembolic events when compared with that of the cisplatin-based regimen.¹³ The results of FLO regimen raised the interest of using this regimen with docetaxel instead of the classical CF regimen.²⁰

In 2008, Al-Batran, in a Phase II trial with FU, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in metastatic gastric cancer, showed a significant response rate of 57.7%, with a median PFS of 5.2 months and an OS of 11.1 months in the Western population. The quadruple FLOT regimen has been the new standard of care for locally advanced and resectable gastric adenocarcinoma after the FLOT-4 study. Indian gastric cancers are extremely cachexic with poor oral intake at the time of diagnosis and have varied tolerance with

increased toxicities while treated with standard DCF regimen. Using lower doses of docetaxel and replacing cisplatin with oxaliplatin in FLOT compared with standard DCF was hypothesized to improve survival outcomes with a better toxicity profile; hence, this study was taken up to assess the safety and efficacy of FLOT chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel in our patient population.

Materials and Methods

Study Design

This is a single-center, prospective study of patients with locally advanced and metastatic gastric adenocarcinoma who required chemotherapy, treated at Amrita Institute of Medical Sciences, Kochi, between March 2016 and November 2017.

Inclusion Criteria

1. Those with histologically confirmed or biopsy-proven adenocarcinoma of the stomach who receive chemotherapy with FLOT regimen
2. Those with age >18 years
3. Those with Eastern Cooperative Oncology Group²¹ PS 2 or less
4. Those with no history of synchronous or double malignancy
5. Those in locally advanced gastric cancer (defined as clinical stages T3N1 or T4N1 as determined by computed tomography [CT] scans and endoscopic ultrasonography)
6. Patients willing to abide and sign an informed consent.

Exclusion Criteria

1. Patients with proven preexisting peripheral neuropathy.
2. Those with brain metastasis.
3. Those with cancers arising from the gastroesophageal junction and squamous cell histology.
4. Those with cardiac dysfunction, human immunodeficiency virus-positive patients, or those with other immunodeficiency syndromes
5. Those with a history of hypersensitivity to FLOT chemotherapeutic drugs.

The FLOT four-drug regimen constitutes 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel. The dose of each drug was as follows: 5-FU at 1200 mg/m²/day as a 24-hour infusion on days 1 and 2, docetaxel at 50 mg/m², and oxaliplatin at 85 mg/m² each as a 2-hour intravenous (IV) infusion on day 1. Injection leucovorin at 400 mg/m² was administered as IV infusion on days 1 and 2. The drugs were cycled every 2 weeks or once in 14 days, and up to a total of eight cycles were given for patients with metastatic disease. In locally advanced gastric adenocarcinoma, four cycles of neoadjuvant (preoperative) chemotherapy followed by surgery and four more cycles of adjuvant (postoperative) chemotherapy were planned. Reassessment was performed at the completion of four cycles of FLOT, and toxicities were noted at the end of every cycle.

Standard antiemetic prophylaxis was done as per institution protocols. Prophylactic dexamethasone 8 mg was administered (days: 0–2) to prevent fluid retention and allergic reactions. Three doses of prophylactic growth factors (granulocyte colony-stimulating factor or Grafeel 300 µg subcutaneous once daily for 3 days) from day 3 of chemotherapy after each cycle were permitted. In patients with Grade IV toxicities or febrile neutropenia, 50% dose reduction was permitted with increase in use or prophylactic growth factor.

Before treatment, a complete general physical examination along with past medical history, complete blood count, blood chemistry, and pretreatment CT scans of chest, abdomen, and pelvis (CAP) was done 3 weeks prior to start of the treatment.

Toxicity was evaluated before the start of each cycle as per the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) version 3.0.

For every four cycles, the objective response was evaluated as per the Response evaluation criteria in solid tumors (RECIST) criteria v1.1 based on a CT-scan of CAP (magnetic resonance imaging, when indicated) and they were compared with a baseline CT scan.

In the locally advanced setting, patients received four cycles of neoadjuvant chemotherapy followed by four more cycles after surgery and in the metastatic setting, a maximum of eight cycles of biweekly chemotherapy were planned. The primary objective was to evaluate the safety and efficacy of the regimen, whereas the secondary objective was OS and PFS.

Statistical Analysis

The data were analyzed using IBM SPSS software (Version 20.0 for Microsoft). With FLOT regimen, the efficacy was calculated using the percentage of cases with response to treatment.

Kaplan–Meier survival curves were plotted to measure the OS rates and PFS rates.

OS is defined as the time from randomization to death from any cause.

PFS is defined as the time from randomization until the first evidence of tumor progression or until death from any cause, whichever comes first.

Ethics

The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional) and with the Helsinki Declaration of 1964, as revised in 2013. Ethical committee approval was obtained from Amrita Institute of Medical Sciences Ethics Committee, IEC-AIMS-2017-MEDONCO-472 on 26–12–2017. Informed patient consent was obtained prior to enrolment of participants.

Results

A total of 28 patients were treated with the FLOT chemotherapy regimen. Their mean age was 55.7 ± 9.8 years (range, 28–70 years), and there was a male preponderance

(89.3%). ►Table 1 depicts the demographics of patients with gastric adenocarcinoma included in the study.

Among the 28 patients, nearly 90% of the patients had stage IV disease, that is, 25 patients had metastatic disease (89.3%), while locally advanced disease (10.7%) was noted in three patients. Six patients (21.4%) had undergone prior tumor removal or gastrectomy who later relapsed. Various prior treatments are summarized in ►Table 2.

Among the 25 patients (89.3%) with metastatic disease, 32% had metastasis to liver parenchyma, followed by a colon

Table 1 Patients' general characteristics with locally advanced and metastatic adenocarcinoma of stomach

General characteristics	Number of patients, n (%)
Stage	
III	3 (10.7)
IV	25 (89.3)
Sex distribution	
Male	25 (89.3)
Female	3 (10.7)
Lauren classification	
Diffuse	14 (50.0)
Intestinal	14 (50.0)

Table 2 Various previous treatments received

Prior treatment	n (%)
Surgery	6 (21.4)
Perioperative chemotherapy	6 (21.4)
Radiation	1 (3.5)
No prior treatments	22 (78.5)

Table 3 Different sites of metastasis at the time of presentation

Site of metastasis	Number of patients, n (%)*
Liver	9 (32.1)
Colon	6 (21.2)
Peritoneum with ascites	4 (14.2)
Omentum	4 (14.2)
Peritoneum	2 (7.1)
Lung	1 (3.5)
Ovary	1 (3.5)
Bone	1 (3.5)
Adrenal	1 (3.5)
Skin	1 (3.5)

Note: * signifies the various sites of metastasis and the commonest site of involvement at the time of diagnosis.

(21%), peritoneal, and ascites (17.8%). One in five patients who received FLOT had metastasis to two or more locations at the time of diagnosis (►Table 3).

Safety

A total of 139 cycles of FLOT were administered, with a mean of 4.5 cycles per patient (range, 1–8), and majority (75%) of the recruited patients received at least four cycles (n = 21).

The most common hematological toxicity was all-grade neutropenia (75%), followed by febrile neutropenia in ten patients (35.7%). The most common nonhematological toxicities were fatigue and mucositis. Various hematological and nonhematological toxicities are depicted in ►Tables 4 and 5, respectively. As a result of increased adverse events, dose modification was noted in 57.12% (16) of the patients after a mean of 3.1 cycles.

Chemotherapy with FLOT had to be discontinued in seven patients (25%) after one cycle due to various reasons. The cause of discontinuation was cardiac arrest in two patients (one

succumbed to neutropenic sepsis with septic shock, while the other had a probable 5-FU-related coronary vasospasm), one patient developed a cerebrovascular accident (embolism in the right cerebral hemisphere), three had Grade IV neutropenia with thrombocytopenia, and one had severe fatigue and Grade IV vomiting and refused further chemotherapy.

Efficacy

Among the 28 patients who received FLOT chemotherapy, only 21 had completed at least four cycles of biweekly chemotherapy, whereas seven patients discontinued after receiving one cycle.

Two deaths were noted prior to the initial CT scan evaluation and were considered as disease progression. Out of the 28 patients, 11 had an objective response with an intent-to-treat (ITT) objective response rate of 52.3%, with the best-obtained response being a partial response (PR) with two patients having stable disease. ►Table 6 shows the responses obtained to FLOT chemotherapy.

Table 4 Hematological toxicities associated with fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy regimen

Toxicity	Grade	Number of patients	Total, n (%)
Neutropenia	2	6	20 (71.4)
	3	9	
	4	5	
Anemia	2	3	7 (25.0)
	3	3	
	4	1	
Thrombocytopenia	2	2	7 (25.0)
	3	2	
	4	3	

Table 5 List of nonhematological toxicities with fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy regimen

Toxicity	Grade	Number of patients	Total, n (%)
Mucositis	2	0	10 (35.7)
	3	9	
	4	1	
Peripheral neuropathy	2	4	9 (32.1)
	3	4	
	4	1	
Diarrhea	2	2	8 (28.5)
	3	6	
	4	6	
Fatigue	2	0	10 (35.7)
	3	6	
	4	4	

Table 6 Responses obtained to fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy

Responses obtained	Number of patients, n (%)
CR	0
PR	11 (39.2)
ORR = CR + PR	11 (39.2) on ITT analysis, ORR = (52.3)
Progression	10 (35.7)
Stable disease	2 (7.1)
Response not assessed	5 (17.8)

Abbreviations: CR, complete response; ITT, intent-to-treat; ORR, overall response rate; PR, partial response.




Fig. 1 The disease-free survival (DFS) for the study group was 5 months (95% confidence interval: 1.78–8.21).




Fig. 2 The overall survival (OS) for fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy was 13 months (95% confidence interval: 8.14–17.85).

The median time to progression was 5 months (95% confidence interval [CI] [1.78–8.21]) [► Fig. 1], with a median OS of 13 months (95% CI [8.14–17.85]) (► Fig. 2). PFS at 1 year for stage III and stage IV on FLOT was 50 and 30%, respectively, (95% CI [0.226–4.435]), $p = 0.005$ (log rank test).

Discussion

The biology of gastric cancer is extremely unique and aggressive by behavior, with most of them being either metastatic or locally advanced and inoperable at the time of diagnosis. Despite all efforts in oncology, improving survival and quality of life has been challenging in gastric adenocarcinoma. Platinum, taxane, and fluoroquinolone compounds in various two or three drug combinations have been the mainstay of treatment in gastric adenocarcinoma since the early 90s in both locally advanced and metastatic scenarios. Treating gastric adenocarcinoma with the right combination at the optimal therapeutic dose with tolerable side effects might most likely improve responses that translate into a survival benefit.

In our study, we intended to assess the safety and tolerability of the FLOT regimen. On ITT analysis, the overall response rate was 52.3%, with PR being the best-obtained response. The median time to progression was 5 months and the median OS was 13 months with significantly increased adverse events and more than half of the patients in the study needed dose modifications.

The response rates were very similar to that of the reported literature, with most of the regimens being active in gastric cancer such as ECF, XP, FOLFOX, or EOX, at a rate of $\sim 45\% \pm 10\%$.⁹

In the landmark study, REAL-2, the median OS to ECF, XP, FOLFOX, or EOX was between 9 and 13.3 months, with a 13-month OS with FLOT regimen in our study. The reason for no significant improvement in median OS in our patients with

gastric cancer is probably multifactorial, as the majority of our patients are emaciated, with low socioeconomic status and had a significant weight loss either due to advanced disease (cancer cachexia per se) or low food intake with an average weight of patients in our study being 53 kg with a mean body surface area of 1.525.

There was a significant increase in hematological and non-hematological adverse events with Grades III to IV neutropenia in more than half of patients despite receiving three doses of prophylactic growth factors with every cycle. Higher grades of febrile neutropenia were seen in one-third of the patients (35.7%) with FLOT regimen. Increased all-grade gastrointestinal toxicity in the form of severe diarrhea and vomiting was documented in 21.4 and 10.7% of the patients, respectively. Similarly, increased hematological and gastrointestinal adverse events were reported with three-drug DCF regimen in the V325 study and Al-Batrans' 2008 FLOT study with 48% Grades III to IV neutropenia and 14.8% Grades III to IV diarrhea.

More than half (57.1%) of the patients needed dose modifications due to chemotherapy-related adverse effects, with over a quarter of the patients stopping further chemotherapy after one cycle due to various reasons, mostly due to toxicity-related discontinuation.

The neurotoxicity related to oxaliplatin and docetaxel is well known and is the primary reason for stopping the chemotherapy. As both drugs cause peripheral neuropathy, we were cautious about combining them, but surprisingly, neurotoxicity was not very high with this regimen—the 17.8% of Grade III to IV peripheral neuropathy in our study was similar to the 17% reported in the GATE study.²²

Within the limitations of small sample size, FLOT chemotherapy regimen has had some activity in linitis plastica, which is relatively chemoresistant,²³ and among 13 patients with diffuse gastric cancer, we observed four PRs corresponding to a response rate of 30.7%. The best response documented in diffuse gastric carcinoma with signet ring cell morphology was a PR.

Four patients had extensive omental deposits with ascites at the time of presentation; after initiating FLOT chemotherapy, ascites disappeared after three cycles in three patients (75%), which suggests that it is an active regimen in extensive peritoneal disease as well.

Our patients with gastric adenocarcinoma seem to have very poor tolerance to the FLOT chemotherapy regimen with significant toxicities; hence, alternative or modified regimens need to be explored to improve outcomes. The need of hospitalization for 2 days and peripheral venous access such as a peripherally inserted central catheter line to administer chemotherapy is also a major challenge as many a time the cost of treatment has to be borne by the patient himself/herself from his/her own expenditure with no health insurance. Hence, quadruple FLOT regimen should be considered only in a patient with good performance status and no significantly associated comorbidities.

Conclusion

FLOT chemotherapy regimens induced excellent responses in locally advanced and metastatic adenocarcinoma of the

stomach but with significantly increased adverse events, needing dose modifications in nearly two-thirds of the patients and hence, it should be considered only in a young patient with good performance status and no associated comorbidities.

Financial Support and Sponsorship

Nil.

Conflicts of Interest

There are no conflicts of interest.

References

- Rao DN, Ganesh B. Estimate of cancer incidence in India in 1991. *Indian J Cancer* 1998;35(01):10–18
- Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. *Ann Oncol* 2003;14(Suppl 2):ii31–ii36
- Pavithran K, Doval DC, Pandey KK. Gastric cancer in India. *Gastric Cancer* 2002;5(04):240–243
- Yeole BB. Trends in cancer incidence in esophagus, stomach, colon, rectum and liver in males in India. *Asian Pac J Cancer Prev* 2008;9(01):97–100
- Satyanarayana L, Asthana S. Life time risk for development of ten major cancers in India and its trends over the years 1982 to 2000. *Indian J Med Sci* 2008;62(02):35–44
- Rastogi T, Devesa S, Mangtani P, et al. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. *Int J Epidemiol* 2008;37(01):147–160
- Ajani JA. Evolving chemotherapy for advanced gastric cancer. *Oncologist* 2005;10(Suppl 3):49–58
- Foukakis T, Lundell L, Gubanski M, Lind PA. Advances in the treatment of patients with gastric adenocarcinoma. *Acta Oncol* 2007;46(03):277–285
- Van Cutsem E, Moiseyenko VM, Tjulandin S, et al; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 2006;24(31):4991–4997
- Ajani JA, Moiseyenko VM, Tjulandin S, et al; V-325 Study Group. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. *J Clin Oncol* 2007;25(22):3210–3216
- Ajani JA, Moiseyenko VM, Tjulandin S, et al; V-325 Study Group. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. *J Clin Oncol* 2007;25(22):3205–3209
- Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase ii study of modified docetaxel, cisplatin, and fluorouracil (DCF) Versus DCF Plus growth factor support in patients with metastatic gastric adenocarcinoma: A study of the US gastric cancer consortium. *J Clin Oncol* 2015;33(33):3874–3879
- Hejna M, Raderer M, Zacherl J, et al. Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS.1.2.001. *Anticancer Drugs* 2008;19(05):535–539
- Kim JG, Sohn SK, Chae YS, et al. Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group. *Br J Cancer* 2008;98(03):542–546
- Park Y, Kim K, Choi M, et al. A Phase I/II trial of docetaxel (D) and oxaliplatin (O) in patients with advanced gastric cancer (AGC). In: 2008 ASCO annual meeting proceedings (post-meeting edition). *J Clin Oncol* 2008;26:155
- Richards D, McCollum D, Wilfong L, et al. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. *Ann Oncol* 2008;19(01):104–108
- Al-Batran SE, Hartmann JT, Probst S, et al; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol* 2008;26(09):1435–1442
- Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. *J Clin Oncol* 2004;22(04):658–663
- Al-Batran SE, Kerber A, Atmaca A, et al. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. *Onkologie* 2007;30(1-2):29–34
- Al Batran S, Hartman J, Hofheinz R, et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: A Phase II trial of the Arbeitsgemeinschaft internistische Onkologie. *Ann Oncol* 2006;19:1882–1887
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5(06):649–655
- Cutsem VE, Boni C, Tabernero J, et al. Randomized Phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. *J Clin Oncol* 2011(Suppl):4018
- Messenger M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette CFREGAT working group - FRENCH. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. *Ann Surg* 2011;254(05):684–693, discussion 693